Combination Drug Products' Eligibility For Patent Term Extension Is Limited, Court Says
This article was originally published in The Pink Sheet Daily
Executive Summary
At least one of the active ingredients "must be new to the marketplace," a federal appeals court says in denying a patent extension for Abbott's Vicoprofen. The ruling could have a significant impact on big pharma companies that are eyeing combo therapies as growth drivers.
You may also be interested in...
Merck/Schering’s Zetia/Zocor Combo Is Vytorin
Merck and Schering-Plough have selected Vytorin as the brand name for the ezetimibe/simvastatin fixed-dose combination
Pfizer’s Double Dose Of Good News: Caduet Combo, Spiriva Clear FDA
Caduet clears FDA for the "simultaneous treatment of high blood pressure and high cholesterol," Pfizer says. The Norvasc and Lipitor combination product could broaden Pfizer’s reach in the cholesterol market.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.